The warning links Ozempic to a condition known as ileus, which can cause abdominal cramps, bloating, nausea, vomiting, constipation, difficulty passing gas and difficulty eating
However, sometimes GLP-1s dont cause rapid weight decline
Who might benefit most: People whove had partial response to current GLP-1 therapy Patients who need stronger appetite/satiety support Those who want an option that may compete with (or exceed) todays injectable results, depending on final labeled data 3) Retatrutide (triple G) a triple-hormone incretin approach What it is: Retatrutide is a triple hormone receptor agonist (GLP-1, GIP, and glucagon)
Wegovy may be covered for heart disease prevention or MASH, but coverage for weight management is less consistentsome states cover it, others dont
Our tools and coaching programs are designed to integrate seamlessly with any coverage modelensuring that, no matter how access is structured, members receive the support they need to succeed, and employers maintain control over outcomes and costs